Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B+
Novartis has licensed a new stem cell therapy from Mesoblast, just weeks after the FDA rejected the Australian biotech’s pitch for an approval on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
